Pear, tight on cash, considers strategic alternatives

The digital therapeutics firm is considering a sale, merger, divestiture, licensing, or seeking additional financing. 

By Elise Reuter • March 17, 2023

Senseonics grows sales in Q4 despite ‘softer demand’ for CGM implant in US and Germany

Demand in the U.S. was affected by “a little bit of ambiguity on pricing” ahead of a change to Medicare.

By Nick Paul Taylor • March 17, 2023

iRhythm beats Q4 expectations, shares rise on Zio XT account openings

Progress on addressing operational issues, along with increased Zio sales, drove revenue growth, analysts said.

By Susan Kelly • Feb. 24, 2023

Insulet exceeds sales forecast amid signs Omnipod 5 is winning share in diabetes pump market

The pump will be a “share taker for some time to come,” as patients switch from rival devices, said Insulet’s CFO.

By Nick Paul Taylor • Feb. 24, 2023

Tandem sees growth in new product launches after $95M loss on decline in pump placements

Craig Hallum analysts said 2022 was a “tough year” for Tandem but noted the company’s 2023 forecast should “properly” set expectations.

By Elise Reuter • Feb. 23, 2023

Globus’ full-year sales top $1B as analysts continue to question wisdom of NuVasive takeover

Analysts raised concerns about Globus’ planned $3.1 billion takeover of spine specialist NuVasive, asking about the company’s “flexibility and willingness to close the deal.” 

By Nick Paul Taylor • Feb. 23, 2023

Smith+Nephew posted underlying sales growth in Q4; profit slides

The company has made progress with product availability even as it still faces supply chain issues with semiconductors, resins and sterilization capacity.

By Nick Paul Taylor • Feb. 23, 2023

Medtronic boosts full-year outlook as supply challenges subside

The medical device maker said its cardiovascular and neuroscience units helped drive quarterly revenue growth.

By Susan Kelly • Feb. 21, 2023

Henry Schein Q4 profit drops, hurt by falling sales of COVID test kits, PPE

Flu and COVID-19 cases increased appointment cancellations and added to staffing shortages in the quarter.

By Nick Paul Taylor • Feb. 17, 2023

Labcorp expects 2023 revenue growth, helped by Ascension testing agreement

The company’s business model is shifting as the diagnostics firm prepares to spin off its drug development business and expands management of hospital testing labs.

By Elise Reuter • Feb. 16, 2023

Embecta raises 2023 earnings forecast after better-than-expected start

Almost a year after the company spun off from Becton Dickinson, CEO Dev Kurdikar said Embecta’s quarterly results “exceeded our initial expectations” in a challenging market.

By Elise Reuter • Feb. 15, 2023

Baxter to cut about 3,000 jobs after earnings slump on supply chain woes

The economic slowdown also hurt profit in the period even as the company posted double-digit sales growth.

By Nick Paul Taylor • Feb. 10, 2023

Dexcom reports another record year of new customers amid continued demand for G6 device

The diabetes tech firm aims to keep boosting awareness of its CGMs with another Super Bowl commercial.

By Elise Reuter • Feb. 9, 2023

Illumina posts sales slump in Q4, bets on new sequencing machine to drive 2023 growth

Management is looking to the newly launched NovaSeq X system to help return the company to profitability this year.

By Nick Paul Taylor • Feb. 8, 2023

Diagnostic firms turn to restructuring in bid to preserve cash: Goldman

The moves could lead to underfunding, delay or cancellation of research and development projects, the analysts say.

By Nick Paul Taylor • Feb. 7, 2023

Medtech earnings highlights: Easing of macro pressures, accelerated growth in 2023

Still, the latest round of quarterly results show that hospital staffing and supply chain remain a challenge.

By Nick Paul Taylor • Feb. 6, 2023

Zimmer Biomet Q4 net loss widens on supply problems; CEO targets acquisitions

The company plans to enter higher-growth markets, even outside of orthopedics, in a bid to increase revenue.

By Elise Reuter • Feb. 3, 2023

Quest cuts 2023 COVID tests forecast amid continued slump in demand; Q4 profit plunges

The company performed 1.2 million molecular tests in the fourth quarter, down from 1.9 million in the third quarter and 5.4 million one year ago.

By Nick Paul Taylor • Feb. 3, 2023

BD raises full-year forecast, sees Q1 strength in pharmacy automation, pre-fillables

The company’s base businesses helped cushion the impact of declining COVID-19 testing demand.

By Susan Kelly • Feb. 2, 2023

Siemens Healthineers forecasts revenue growth to accelerate despite supply chain woes

Lower diagnostics revenue hurt sales in the three months ended Dec. 31.

By Nick Paul Taylor • Feb. 2, 2023

Boston Scientific gets Q4 boost from heart, urology sales

Following a series of significant acquisitions, the company said it expects net sales growth of about 5% to 7% in full-year 2023.

By Susan Kelly • Feb. 1, 2023

Edwards posts Q4 profit, reaffirms 2023 outlook as patients return

The heart valve specialist said it is optimistic that the healthcare environment will gradually improve this year.

By Susan Kelly • Feb. 1, 2023

Stryker expects 2023 growth despite 15% dip in Q4 net income

CEO Kevin Lobo said he expects new product launches and device orders will offset continued “macroeconomic volatility.”

By Elise Reuter • Feb. 1, 2023

GE HealthCare posts revenue growth in last quarter before spinoff on imaging, ultrasound units

The company benefitted from “robust end-market demand, improved pricing, and easing supply chain pressures” in the period.

By Peter Green • Jan. 30, 2023

ResMed quarterly revenue beats estimates as supply chain woes ease

Demand for CPAP devices and respirators remains strong as the company expects to pick up additional market share from rival Philips, and demand grows for its medical SaaS products.

By Susan Kelly • Jan. 27, 2023